ASH Data On CRS Helps Determine Where Anti-CD20 Bispecifics Fit Versus CAR-T
From the CD20-directed bispecific antibody studies presented at ASH, the risk and severity of cytokine release syndrome is being viewed as a way to determine whether the bispecifics will be used before, after or instead of CAR-Ts.
